Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients

NCT06574984

Status	RECRUITING
Sponsor	Novo Nordisk A/S
Enrollment	900 participants

Key Eligibility Criteria

Inclusion (3)

- Paediatric and adult male patients
- On-demand and prophylactic patients with haemophilia A (any severity)
- Only previously treated patients (previous FVIII replacement therapy) will be included in the study

Exclusion (2)

- Patients diagnosed with coagulation disorders other than haemophilia A such as Von Willebrand disease
- Patients with documented presence of any FVIII inhibitor

Locations (7 total)

National centre for Hamophilia, Baghdad, Iraq
Novo Nordisk Investigational Site, Baghdad, Iraq
Basrah Haemoplhilia centre, Basra, Iraq
... and 4 more locations